secwatch.observer — SEC 8-K summary
======================================

Issuer:     Barinthus Biotherapeutics plc. (BRNS)
CIK:        0001828185
Form:       8-K
Filed at:   2024-11-25T23:59:59+00:00
Accession:  0001828185-24-000093
Event type: leadership
Sentiment:  neutral
Materiality: 0.45
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Barinthus Bio promotes Geoffrey Lynn to CSO; Nadège Pelletier steps down
------------------------------------------------------------------------

- Nadège Pelletier to step down as Chief Scientific Officer effective Feb 2, 2025; she served since early 2023.
- Geoffrey Lynn, M.D., Ph.D. promoted to CSO effective Dec 1, 2024; he is co-inventor of SNAP-TI technology.
- Lynn previously led Avidea Technologies (acquired by Barinthus in 2021) and holds M.D. from Johns Hopkins, D.Phil. from Oxford.
- Company highlights pipeline progress: VTP-300 in chronic hepatitis B, VTP-1000 (SNAP-TI) in Phase 1 for celiac disease.
- Transition expected to be smooth; Pelletier will remain until responsibilities transitioned.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1828185/000182818524000093/0001828185-24-000093-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1828185/000182818524000093/brns-20241125.htm
  HTML page:      https://secwatch.observer/filing/0001828185-24-000093

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer